Zhu, Li <br/><br/>
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jul 2004 
 - 4639-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-04-0057  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Androstadienes--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Aromatase Inhibitors--therapeutic use<br/>Breast Neoplasms--genetics<br/>Celecoxib<br/>Cyclooxygenase Inhibitors--therapeutic use<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunohistochemistry<br/>In Situ Hybridization, Fluorescence<br/>Letrozole<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Nitriles--therapeutic use<br/>Prognosis<br/>Pyrazoles--therapeutic use<br/>Receptor, ErbB-2--analysis<br/>Sulfonamides--therapeutic use<br/>Treatment Outcome<br/>Triazoles--therapeutic use